Germline APOBEC3B deletion influences clinicopathological parameters in luminal-A breast cancer: evidences from a southern Brazilian cohort
Authors:
- Glauco Akelinghton Freire VitielloGlauco Akelinghton Freire Vitiello
- Nathalia de Sousa PereiraNPNathalia de Sousa Pereira
- Marla Karine AmaranteMAMarla Karine Amarante
- Bruna Karina Banin-HirataBBBruna Karina Banin-Hirata
- Karen Brajão de OliveiraKOKaren Brajão de Oliveira
- Roberta Losi-GuembarovskiRLRoberta Losi-Guembarovski
- Maria Angelica Ehara WatanabeMWMaria Angelica Ehara Watanabe
- 13 April 2020
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 146 (6) , 1523-1532
Abstract
Purpose APOBEC3A and APOBEC3B cytidine deaminases have been implicated in the pathogenesis of multiple cancers, including breast cancer (BC). A germline deletion linking APOBEC3A and APOBEC3B loci (A3A/B) has been associated with higher APOBEC-mediated mutational burden, but its association with BC risk have been controversial. Therefore, this study investigated the association between A3A/B and BC susceptibility and clinical presentation in a Brazilian cohort. Methods A3A/B deletion was evaluated through allele-specific PCR in 341 BC patients and 397 women without familial or personal history of neoplasia from Brazil and associations with susceptibility to BC subtypes were tested through age-adjusted logistic models while correlations with clinicopathological parameters were tested using Kendall’s tests. Results No association was found between A3A/B and BC susceptibility; however, in Luminal-A BCs, it was positively correlated with tumor size (Tau-c = 0.125) and Ki67 (Tau-c = 0.116) and negatively correlated with lymph node metastasis (LNM) (Tau-c = − 0.162). The negative association between A3A/B with LNM in Luminal-A BCs remained significant even after adjusting for tumor size and Ki67 in logistic models (OR = 0.22; p = 0.008). Conclusion These results show that although A3A/B may not modify BC susceptibility in Brazilian population, it may affect clinicopathological features in BC subtypes, promoting tumor cell proliferation while being negatively associated with LNM in Luminal-A BCs.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (304348/2019-8)
This publication has 46 references indexed in Scilit:
- APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapyNature Communications, 2020
- Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer typesBMC Medical Genomics, 2019
- APOBEC3A/B deletion polymorphism and cancer riskCarcinogenesis, 2017
- An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancersNature Genetics, 2015
- APOBEC3Bexpression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activationProceedings of the National Academy of Sciences, 2015
- APOBEC3B: Pathological consequences of an innate immune DNA mutatorBiomedical Journal, 2015
- A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3′UTR enhances chromosomal DNA damageNature Communications, 2014
- Evidence for APOBEC3B mutagenesis in multiple human cancersNature Genetics, 2013
- APOBEC3B is an enzymatic source of mutation in breast cancerNature, 2013
- A Human Genome Diversity Cell Line PanelScience, 2002